180 Life Sciences Corp. announced that the Company and its regulatory consultants from the US and the UK, met with the UK Medicines and Healthcare products Regulatory Agency (MHRA) scientific advice committee for the second time on October 31, 2022. The Company provided additional data to MHRA concerning the use of nodule size and hardness as surrogate markers relating to eventual finger contraction in Dupuytren's disease, and raised a series of questions to MHRA.

On November 23, 2022, the Company received formal written scientific advice regarding such matters. The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD) trial and the data provided by the Company. They noted that it has not been shown that reducing nodule size via treatment would lead to improvements in terms of disease progression, which the Company understands, and requested support for a correlation with clinical outcomes.

The MHRA also asked for additional literature supporting the clinical safety of adalimumab from other approved indications such as rheumatoid arthritis. The Company plans to provide further information to the MHRA to address its comments.